| DB ID | MyCo_2321 |
| Title | Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease |
| Year | 2014 |
| PMID | 25007380 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | Hematologic malignancies. |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by institutional ethics committee (Department of Biomedicine, University Basel, Basel, Switzerland) and subjects provided written informed consent. |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Switzerland |
| Cohort | A total of 568 hematologic cases undergoing diagnostic bronchoscopy because of respiratory symptoms and/or suspected IFD between 2009 and 2013 at a tertiary care center in Switzerland were included in this prospective, observational cohort study. Immunocompromised hematologic patients reporting and/or depicting respiratory symptoms and/or signs, such as cough, sputum production, fever, and/or dyspnea, were considered at risk for respiratory infection, respectively IFD, and underwent flexible, diagnostic bronchoscopy at the discretion of the attending hematologic physician. Neither fever nor previous use of antibiotics was required for establishing the indication for bronchoscopy. Inclusion criteria were (1) age greater than 18 years, (2) immunocompromised state as defined by hematologic malignancy, (3) decision by the pulmonary consultant to perform bronchoscopy because of suspected pulmonary infection, and (4) informed consent by the patient to undergo flexible bronchoscopy and related data analysis. Exclusion criteria were pregnancy and inability to provide informed consent. |
| Cohort No. | 568 |
| Age Group | Greater than 18 |
| P Value | p<0.001 |
| Sensitivity | 0.5 |
| Specificity | 0.73 |
| Positive Predictive Value | 0.16 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive bronchopulmonary aspergillosis accounts for 30–50% of invasive fungal diseases (IFD) among immunocompromised patients with hematologic malignancies. The lung is the most affected organ by Aspergillus species infections and the mortality and morbidity among immunocompromised patients, despite the use of newer antifungal agents, reaches 20%. Even though most patients at highest risk for IFD never develop this condition, IFD carries a devastating prognosis. Therefore, it is crucial to improve early and correct diagnosis, thus identifying patients who really need treatment and avoiding unnecessary toxicity and costs. The diagnosis of IFD remains challenging and is based on a combination of clinical factors, host factors, and microbiologic criteria. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit (Platelia Aspergillus; BioRad Laboratories, Hercules, CA) (25). |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
